Erythropoietin Drugs Market Scope
The global erythropoietin drugs market size is expected to witness a growth in the forecast period due to an increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV. Erythropoietin drugs are also known as hematopoietic. It is a glycoprotein hormone that controls erythropoiesis or the production of RBC. To curb the rising incidence of anemia, the demand for Erythropoietin (EPO) drugs is expected to increase over the coming years.
The Erythropoietin Drugs market study is segmented by Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others), by Application (Anemia (Cancer and HIV treatment), Kidney Disorders (ESRD and Dialysis) and Others (Neural Disease and Wound healing)) and major geographies with country level break-up.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Erythropoietin Drugs market throughout the predicted period.
Hoffmann-La Roche (Switzerland), Johnson & Johnson (United States), Amgen (United States), Kyowa Hakko Kirin (Japan), Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India), Celltrion, Inc. (South Korea), Hospira (United States) and Dahua Pharmaceutical (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are LG Life Sciences Ltd. (Korea), 3SBio (China), Boehringer Ingelheim (United States) and BIOSIDUS (Argentina).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Erythropoietin Drugs market by Type, Application and Region.
On the basis of geography, the market of Erythropoietin Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In May 2018, The U.S. Food and Drug Administration approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery.
- Growing Commercialization for Erythropoietin Biosimilars
- Increasing Number Cases Including Cancer,HIV, Kidney Disease and Anaemia
- Rising Awareness about the Benefits of EPO Therapeutics
- Commercialization of Darbepoetin Alfa Biosimilar
- Achieving Economies of Scale Across Developed Region with Biosimilar Version of EPO
- High Cost of the Drugs
- Adverse Amount of Side Effects
- Longer Duration of Treatments
Key Target AudiencePharmaceutical companies, Research and Development (R&D) Companies, Government and Independent Research Laboratories, Contract Research Organizations (CROs), Medical Research Laboratories and Academic Medical Institutes and Universities
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase